Looking ahead, rational combinations of systemic PD-1 blockade with locoregional immunotherapies—such as intralesional oncolytic viral therapy (e.g., talimogene laherparepvec) or topical immunomodulators (e.g., imiquimod)—warrant prospective evaluation in advanced cSCC, particularly in immunocompromised and genetically predisposed patients. The gene discussed is RPL17; the disease is skin squamous cell carcinoma.